Trastuzumab biosimilar - Shanghai CP Guojian PharmaceuticalAlternative Names: Cipterbin; CMAB 302
Latest Information Update: 20 Aug 2015
At a glance
- Originator Shanghai CP Guojian Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 20 Aug 2015 Phase III development is ongoing in China, Company website mentions drug as soon to be launched product